MESEMBRENOL AND/OR MESEMBRANOL FOR PROPHYLAXIS AND TREATMENT OF PATIENTS SUFFERING FROM EPILEPSY AND ASSOCIATED DISEASES
申请人:HG&H Pharmaceuticals (Pty) Ltd
公开号:US20200215033A1
公开(公告)日:2020-07-09
The invention relates to the alkaloids mesembranol or mesembrenol, or pharmaceutical acceptable salts or complexes thereof, for use in the prophylaxis or treatment of a disease that responds to treatment with an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist. The prophylaxis or treatment attenuates AMPA mediated neurotransmission in the hippocampus of a subject.